ABSTRACT
BACKGROUND: Decompensated cirrhosis due to hepatitis C virus (HCV) is one of the main indications for liver transplantation (LT) in Spain. Recurrence of HCV after LT is the main cause of graft loss and death in HCV-positive recipients. Advanced donor age determines a more aggressive recurrence of HCV and a shorter survival. In this setting, in our liver unit, grafts from younger donors are allocated to HCV-positive recipients. The aim of this study was a comparative analysis of allocation of grafts in HCV-positive recipients versus other etiologies and the impact on waiting list time, Model for End-Stage Liver Disease (MELD) score progression until LT, need of admission in a hospital, survival until LT. METHODS: This was a retrospective study from the cohort of patients included in the waiting list for LT owing to decompensated cirrhosis in the Hospital Gregorio Marañón from January 2008 to June 2013. RESULTS: A total of 91 patients were included; 63 patients (69.23%) received LT; 19 (20.88%) retired from the waiting list: 6 because of improvement, 11 (12.08%) because of death. In both groups, the age of recipients was similar (HCV 52 y vs other 53 y; P = .549). HCV patients were included in the waiting list with lower MELD score than other etiologies (HCV 16.1 vs other 19.4; P = .010); nevertheless, MELD score was similar at the time of LT in both groups (HCV 18.9 vs other 19.4; P = .675). Time on waiting list was significantly longer in HCV patients (198 d vs 86 d; P = .002) and they were admitted in hospital more days (30 d vs 12 d; P = .03). Donor age in the HCV group was significantly lower (64.3 y vs 54.7 y; P = .006). The intention-to-treat survival analysis did not show differences between the groups (log rank = 0.504). CONCLUSIONS: HCV patients with decompensated cirrhosis receive grafts from younger donors. HCV patients remain waiting longer for an optimal organ and suffer MELD deterioration and more days admitted in hospital. These differences in allocation of grafts did not affect final survival. In our experience, designating younger organs to HCV-positive patients does not penalize neither HCV recipients nor recipients with other etiologies.
Subject(s)
Hepacivirus , Hepatitis C, Chronic/complications , Liver Cirrhosis/surgery , Liver Transplantation/statistics & numerical data , Tertiary Care Centers , Transplant Recipients , Waiting Lists , Female , Follow-Up Studies , Hepatitis C, Chronic/virology , Humans , Incidence , Liver Cirrhosis/epidemiology , Liver Cirrhosis/etiology , Male , Middle Aged , Retrospective Studies , Spain/epidemiologyABSTRACT
No disponible
Subject(s)
Humans , Liver Transplantation/adverse effects , Postoperative Complications/diagnosis , Postoperative Complications/etiology , Risk Factors , PrognosisABSTRACT
The prevalence of HCV infection in Spanish prisons is very high (38.5%). The characteristics of the infected patients, particularly the high rate of HIV coinfection, makes it very likely that the morbidity and mortality produced by serious liver disease secondary to this infection will increase considerably in the coming years. A group of Spanish experts with experience in patients who are inmates has been invited to establish a series of recommendations for the diagnosis and treatment of chronic hepatitis C infection in Spanish prisons.
ABSTRACT
La prevalencia de la infección por el virus de la hepatitis C (VHC) en las prisiones españolas es muy elevada (38,5%). Las características de los pacientes infectados, especialmente la elevada coinfección con el virus de la inmunodeficiencia humana (VIH), hacen probable que la morbilidad y mortalidad producida por enfermedad hepática grave secundaria a esta infección aumente de forma considerable en los próximos años. Un grupo de expertos multidisciplinar con experiencia con pacientes internados en prisiones españolas ha sido invitado a establecer una serie de recomendaciones para el diagnóstico y tratamiento de la hepatitis C en las prisiones españolas
The prevalence of HCV infection in Spanish prisons is very high (38.5%). The characteristics of the infected patients, particularly the high rate of HIV coinfection, makes it very likely that the morbidity and mortality produced by serious liver disease secondary to this infection will increase considerably in the coming years. A group of Spanish experts with experience in patients who are inmates has been invited to establish a series of recommendations for the diagnosis and treatment of chronic hepatitis C infection in Spanish prisons
Subject(s)
Male , Humans , Hepatitis C, Chronic/diagnosis , Hepacivirus/pathogenicity , Hepatitis C, Chronic/drug therapy , Practice Guidelines as Topic , HIV Infections/epidemiology , Prisoners/statistics & numerical data , BiopsyABSTRACT
No disponible
No disponible
Subject(s)
Female , Humans , Male , Pharmaceutical Preparations/administration & dosage , Pharmaceutical Preparations/metabolism , Interferons/administration & dosage , Interferons/metabolism , Therapeutics/methods , Therapeutics/nursing , Pharmaceutical Preparations/classification , Pharmaceutical Preparations , Interferons/deficiency , Interferons/supply & distribution , Therapeutics/instrumentation , Therapeutics/standardsABSTRACT
OBJECTIVE: Hepatocellular carcinoma (HCC) ablation by radiofrequency (RFA) is a novel technique with a great variety of methods whose efficacy and predictive factors have not been completely studied. Some of the main predictive factors in this type of treatment are analyzed in the present study. PATIENTS AND METHODS: Ninety-three patients with hepatocellular carcinoma over cirrhosis, and with no indication for surgical resection were treated by RFA. Two different types of electrodes were used for RFA (refrigerated-"Cool-Tip" and perfusion with saline solution, the approach was percutaneous, by laparoscopy or laparotomy. RESULTS: Overall survival at 1, 2 and 3 years was 88, 81, and 76%, with a free-disease survival (FDS) of 66, 31 and 17%, respectively. For tumors less than 3 cm, FDS at 1,2 and 3 years was 74, 44 and 30%, while for more than 3 cm in size FDS was 55, 12 and 0% (p = 0.02). FDS for HCC with one nodule was 70, 36 and 22%, and for more than one nodule it decreased to 50, 17 and 0% at 1, 2 and 3 years, respectively (p = 0.07). Surprisingly, the method employed for RFA has a main influence in FDS, with 0% at 3 years for perfusion electrodes and 26% for cool-tip electrodes at the same period. CONCLUSIONS: In this series, overall survival at three years was relatively high; however, tumoral size, number of nodules and RFS method were independent variables associated with disease-free survival.
Subject(s)
Carcinoma, Hepatocellular/therapy , Catheter Ablation , Liver Neoplasms/therapy , Aged , Carcinoma, Hepatocellular/complications , Female , Humans , Liver Cirrhosis/complications , Liver Neoplasms/complications , Male , Survival Analysis , Treatment OutcomeABSTRACT
The prevalence of systemic thromboembolic complications is higher in patients with inflammatory bowel disease than in the general population. This hypercoagulable state is due to an increased production of procoagulant substances proportionally related to the inflammatory activity of the disease, although recent reports have focused on the presence of inherited thrombophilic disorders in this entity. We present the case of a 32-year-old woman with no relevant medical history who presented with massive abdominal vein thrombosis, including suprahepatic, portal, splenic and superior mesenteric veins, and secondary acute liver failure in her first ulcerative colitis flare and who later developed toxic megacolon requiring emergency total colectomy despite steroids and cyclosporine. Anticoagulant therapy achieved complete resolution of suprahepatic thrombosis and partial resolution in the splenic and superior mesenteric veins, with final cavernous transformation of the portal vein.
Subject(s)
Colitis, Ulcerative/complications , Liver Failure, Acute/complications , Megacolon, Toxic/etiology , Portal System , Venous Thrombosis/complications , Adult , Colitis, Ulcerative/diagnosis , Female , Humans , Liver Failure, Acute/diagnosis , Megacolon, Toxic/diagnosis , Venous Thrombosis/diagnosisABSTRACT
Hepatoportal sclerosis is characterized by fibrosis of the intima of the portal vein and its branches leading to the development of presinusoidal portal hypertension. We describe the case of a 58-year-old woman with idiopathic hepatoportal sclerosis, who was admitted to our service due to impairment of liver function, with rapid clinical worsening and finally the development of multiorgan failure. Autopsy showed a diffuse liver angiosarcoma with splenic metastases. The patient had no history of domestic or occupational exposure to substances involved in the development of hepatoportal sclerosis or liver angiosarcoma. The development of liver angiosarcoma in a patient with hepatoportal sclerosis is exceptional, even though both diseases may have a common etiology.
Subject(s)
Hemangiosarcoma/complications , Hepatic Veno-Occlusive Disease/complications , Liver Neoplasms/complications , Multiple Organ Failure/etiology , Portal Vein/pathology , Autopsy , Fatal Outcome , Female , Hemangiosarcoma/secondary , Humans , Hypertension, Portal/etiology , Liver Failure/etiology , Liver Neoplasms/pathology , Middle Aged , Sclerosis , Splenic Neoplasms/secondaryABSTRACT
Los pacientes con enfermedad inflamatoria intestinal (EII) presentan una prevalencia superior de complicaciones tromboembólicas sistémicas que la población general. Este estado de hipercoagulabilidad se debe a una producción excesiva de sustancias procoagulantes relacionada proporcionalmente con la actividad de la enfermedad, aunque ciertas publicaciones recientes han revelado un número creciente de mutaciones genéticas predisponentes a la trombofilia en estos enfermos. Se presenta el caso de una mujer de 32 años, sin antecedentes patológicos de interés, en la que su primer brote de EII se presentó clínicamente como una trombosis venosa masiva abdominal (que afectaba a las venas suprahepáticas, porta, esplénica y mesentérica superior), con una insuficiencia hepática aguda y el desarrollo posterior de un megacolon tóxico, a pesar de la administración de esteroides y ciclosporina, por lo que se realizó a la paciente una colectomía total urgente. La anticoagulación consiguió la resolución completa de la trombosis de las venas suprahepáticas y parcial de la esplénica y mesentérica superior, con transformación cavernomatosa de la porta
The prevalence of systemic thromboembolic complications is higher in patients with inflammatory bowel disease than in the general population. This hypercoagulable state is due to an increased production of procoagulant substances proportionally related to the inflammatory activity of the disease, although recent reports have focused on the presence of inherited thrombophilic disorders in this entity. We present the case of a 32-year-old woman with no relevant medical history who presented with massive abdominal vein thrombosis, including suprahepatic, portal, splenic and superior mesenteric veins, and secondary acute liver failure in her first ulcerative colitis flare and who later developed toxic megacolon requiring emergency total colectomy despite steroids and cyclosporine. Anticoagulant therapy achieved complete resolution of suprahepatic thrombosis and partial resolution in the splenic and superior mesenteric veins, with final cavernous transformation of the portal vein
Subject(s)
Female , Adult , Humans , Colitis, Ulcerative/complications , Megacolon, Toxic/etiology , Portal System , Venous Thrombosis/complications , Liver Failure, Acute/complications , Colitis, Ulcerative/diagnosis , Megacolon, Toxic/diagnosis , Venous Thrombosis/diagnosis , Liver Failure, Acute/diagnosisABSTRACT
La esclerosis hepatoportal es una enfermedad caracterizada por la fibrosis de la íntima de la vena porta y de sus ramas, que conduce al desarrollo de hipertensión portal presinusoidal. A continuación describimos el caso de una paciente de 58 años de edad, diagnosticada de esclerosis hepatoportal idiopática, que ingresó en nuestro servicio por presentar un deterioro de la función hepática, con un rápido empeoramiento clínico y el desarrollo de un fallo multiorgánico. El estudio de la necropsia demostró la presencia de un angiosarcoma hepático difuso con metástasis esplénicas. La paciente no presentaba antecedentes de exposición a sustancias de riesgo para el desarrollo de esclerosis hepatoportal ni angiosarcoma hepático en su entorno laboral y doméstico. El desarrollo de un angiosarcoma hepático sobre una esclerosis hepatoportal es un hecho excepcional a pesar de que ambas enfermedades poseen una posible etiología común
Hepatoportal sclerosis is characterized by fibrosis of the intima of the portal vein and its branches leading to the development of presinusoidal portal hypertension. We describe the case of a 58-year-old woman with idiopathic hepatoportal sclerosis, who was admitted to our service due to impairment of liver function, with rapid clinical worsening and finally the development of multiorgan failure. Autopsy showed a diffuse liver angiosarcoma with splenic metastases. The patient had no history of domestic or occupational exposure to substances involved in the development of hepatoportal sclerosis or liver angiosarcoma. The development of liver angiosarcoma in a patient with hepatoportal sclerosis is exceptional, even though both diseases may have a common etiology
Subject(s)
Female , Humans , Hemangiosarcoma/complications , Hepatic Veno-Occlusive Disease/complications , Multiple Organ Failure/etiology , Portal Vein/pathology , Liver Neoplasms/complications , Autopsy , Fatal Outcome , Hemangiosarcoma/secondary , Hypertension, Portal/etiology , Hepatic Insufficiency/etiology , Sclerosis , Liver Neoplasms/pathology , Splenic Neoplasms/secondaryABSTRACT
Objetivo: la ablación por radiofrecuencia del hepatocarcinoma(ARF) es una técnica de reciente adquisición, cuya eficacia yfactores predictivos no han sido suficientemente evaluados. Elpresente estudio fue diseñado para este análisis.Pacientes y métodos: se han tratado 93 pacientes con hepatocarcinomasobre hígado cirrótico sin criterios de resección nide trasplante hepático. El tratamiento se realizó mediante abordajepercutáneo, laparoscópico o mediante laparotomía con dos tiposde electrodos de radiofrecuencia, electrodo refrigerado y deperfusión respectivamente.Resultados: la supervivencia global a los 1, 2 y 3 años fue del88, 81 y 76%, con una supervivencia-libre de enfermedad (SLE)de 66, 31 y 17% respectivamente. El análisis multivariante demostrótres variables predictivas independientes: tamaño tumoral( 3 cm; SLE a 1,2 y 3 años de 74, 44 y 30%,frente a 55, 12 y 0%; HR= 2,02; IC 95% 1,10-3,70; p = 0,02),número de nódulos (uno frente a más de uno; SLE a 1,2 y 3 añosde 70, 36 y 22, frente a 50, 17 y 0%; HR= 1,92 IC 95% 0,95-3,93; p = 0,07) y tipo de electrodo (refrigerado frente a perfusión;SLE 80, 43 y 26% a 1, 2 y 3 años frente a 49, 12 y 0%;HR = 2,06; IC 95% 1,12-3,79; p = 0,02).Conclusiones: a pesar de que la ARF proporciona una supervivenciaglobal aceptable, la SLE es notablemente inferior. El tamañodel tumor, el número de nódulos y el tipo de electrodo deARF fueron variables independientes asociadas a la SLE
Objective: hepatocellular carcinoma (HCC) ablation by radiofrequency(RFA) is a novel technique with a great variety ofmethods whose efficacy and predictive factors have not beencompletely studied. Some of the main predictive factors in thistype of treatment are analyzed in the present study.Patients and methods: ninety-three patients with hepatocellularcarcinoma over cirrhosis, and with no indication for surgicalresection were treated by RFA. Two different types of electrodeswere used for RFA (refrigerated-Cool-Tip and perfusion withsaline solution, the approach was percutaneous, by laparoscopyor laparotomy.Results: overall survival at 1, 2 and 3 years was 88, 81, and76%, with a free-disease survival (FDS) of 66, 31 and 17%, respectively.For tumors less than 3 cm, FDS at 1,2 and 3 years was74, 44 and 30%, while for more than 3 cm in size FDS was 55,12 and 0% (p = 0.02). FDS for HCC with one nodule was 70, 36and 22%, and for more than one nodule it decreased to 50, 17and 0% at 1, 2 and 3 years, respectively (p = 0.07). Surprisingly,the method employed for RFA has a main influence in FDS, with0% at 3 years for perfusion electrodes and 26% for cool-tip electrodesat the same period.Conclusions: in this series, overall survival at three years wasrelatively high; however, tumoral size, number of nodules andRFS method were independent variables associated with diseasefreesurvival
Subject(s)
Aged , Humans , Carcinoma, Hepatocellular/therapy , Catheter Ablation , Liver Cirrhosis/therapy , Liver Neoplasms/therapy , Carcinoma, Hepatocellular/complications , Liver Cirrhosis/complications , Treatment Outcome , Survival Analysis , Liver Neoplasms/complicationsSubject(s)
Abdominal Muscles , Hematoma/etiology , Paracentesis/adverse effects , Humans , Male , Middle AgedABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Abdominal Muscles , Abdominal Muscles , Hematoma , ParacentesisABSTRACT
Hepatitis C virus (HCV) has been associated with several autoimmune and rheumatologic disorders. The aim of this study was to determine the incidence of these abnormalities in patients with chronic HCV. We studied 56 patients, 29 of whom (52%) had biochemical abnormalities that suggested immunological disorders. Cryoglobulinemia was detected in nine patients (22%), antinuclear antibodies in eleven (20%), rheumatoid factor in seven (19.27%) and hypocomplementemia in fourteen (29.16%). The most common clinical manifestations were: arthralgias (52%), myalgias (16%), xerostomia (28.5%) and xerophthalmia (14%). These results indicate the existence of a relationship between HCV and rheumatologic disorders. We conclude that HCV may play a role in the pathogenesis of these autoimmune phenomena, but more studies are required to define the extent of this role.
Subject(s)
Autoimmune Diseases/etiology , Hepatitis C/complications , Rheumatic Diseases/etiology , Adult , Aged , Chronic Disease , Female , Humans , Male , Middle Aged , Retrospective StudiesABSTRACT
Splenic artery aneurysms (SAA) are not uncommon in patients with hepatic transplant (HT). Three in 150 transplanted patients in our institutions were diagnosed with SAA and two of them had a spontaneous rupture. In two patients embolization with interventionist radiology was performed with excellent results. SAA should be investigated before and after HT and be treated with embolization as soon as possible because of the high risk of rupture.
Subject(s)
Aneurysm , Liver Transplantation , Splenic Artery , Adult , Aneurysm/etiology , Aneurysm/therapy , Angiography , Embolization, Therapeutic , Humans , Liver Transplantation/adverse effects , Male , Middle AgedABSTRACT
When the hepatic artery is not available in liver transplantation because of its bad quality or low flow, arterial grafts from the donor have to be used to obtain arterial blood flow from the aorta. The case of use of a vascular PTFE prosthesis when no vascular grafts were available is presented, with good outcome 6 months after transplantation.
Subject(s)
Blood Vessel Prosthesis , Liver Transplantation , Liver/blood supply , Polytetrafluoroethylene , Follow-Up Studies , Hepatic Artery , Humans , Male , Middle Aged , Thrombosis , Time FactorsABSTRACT
We report a case of ischemic hepatitis following a percutaneous liver biopsy in a 51 year old female patient, who had had an orthotopic liver transplant 6 months before. The angiographic study demonstrated a marked stenosis in the hepatic artery at the anastomosis site and a small arterioportal fistula. We suggest that the percutaneous liver biopsy was partially responsible for the ischemic hepatitis, due to the development of a small arterioportal fistula in a previously damaged vascular area with hepatic artery stenosis.
